This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Objectives: We examined the relationship between CSF amyloid beta peptide (Aβ) concentration and AD severity in 31 probable AD patients and explored whether APOE genotype modifies this relationship.
Background: Aβ deposition in AD brains has been correlated with disease severity and with APOE-ε4 allele frequency. Few studies have examined the effects of APOE genotype on the relationship between CSF Aβ and disease severity in an antemortem sample.
Methods: Patients carried the clinical diagnosis of probable AD and did not have serious medical illness, current or past diagnosis of mood disorder, schizophrenia or alcoholism, or current psychotic features. The Mini-Mental State Examination (MMSE) was administered to the patient within 3 months of CSF collection. CSF was analyzed for Aβ1-40 and Aβ1-42 by sandwich ELISAs, and APOE genotype was determined by PCR run from blood. Correlations were performed between MMSE score and Aβ1-40 and Aβ1-42 concentrations while controlling for potential confounding variables.
Results: CSF measures of Aβ1-40 and Aβ1-42 concentrations were correlated with each other (r = 0.56, df = 28, p < 0.01). CSF Aβ1-40 and Aβ1-42 concentrations were positively correlated with MMSE score. The negative association between CSF Aβ measures and disease severity remained significant after controlling for age (Aβ1-40 and MMSE score: r = 0.46, df = 28, p = 0.01; Aβ1-42 and MMSE score: r = 0.35, df = 28, p = 0.05). Among the APOE-ε3/3 homozygotes there was a significant positive correlation only between Aβ1-42 and MMSE score (Aβ1-42, r = 0.94, p = 0.02; Aβ1-40, r = 0.79, p = 0.11).
Conclusions: We hypothesize that an increased deposition of Aβ in plaques results in decreased CSF Aβ concentration. The stronger relationship between MMSE score and CSF Aβ, specifically in APOE-ε3/3 homozygotes, suggests that patients with APOE-ε3/3 genotype may have different pathogenic mechanisms than the other genotypes for Aβ deposition or clearance.
- Received September 16, 1997.
- Accepted October 17, 1998.
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
